Dianthus Therapeutics Inc.(DNTH)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

DNTH Dianthus Therapeutics Inc.

交易中 04-29 14:21:03 EDT

82.86

-0.81

-0.97%

最高84.93	最低82.00	成交量32.14万
今开83.15	昨收83.67	日振幅3.50%
总市值45.12亿	流通市值42.59亿	总股本5,445万
成交额2,689万	换手率0.63%	流通股本5,140万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"DNTH","market":"US","secType":"STK","nameCN":"Dianthus Therapeutics Inc.","latestPrice":82.86,"timestamp":1777486860838,"preClose":83.67,"halted":0,"volume":321437,"delay":0,"changeRate":-0.009680889207601318,"floatShares":51401800,"shares":54448771,"eps":-4.203707,"marketStatus":"交易中","change":-0.81,"latestTime":"04-29 14:21:03 EDT","open":83.15,"high":84.925,"low":82,"amount":26889985.81098,"amplitude":0.034959,"askPrice":82.9,"askSize":1,"bidPrice":82.63,"bidSize":244,"shortable":3,"etf":0,"ttmEps":-4.203707,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1777492800000},"marketStatusCode":2,"adr":0,"listingDate":1529553600000,"exchange":"NASDAQ","adjPreClose":83.67,"preHourTrading":{"tag":"盘前","latestPrice":83.01,"preClose":83.67,"latestTime":"09:29 EDT","volume":249,"amount":20811.939165000003,"timestamp":1777469399999,"change":-0.66,"changeRate":-0.007888,"amplitude":0.021394},"postHourTrading":{"tag":"盘后","latestPrice":83.67,"preClose":83.67,"latestTime":"16:15 EDT","volume":13978,"amount":1169586.13,"timestamp":1777407351403,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.018131,"impliedVol":0.6638,"impliedVolPercentile":0.5219},"requestUrl":"/m/hq/s/DNTH","defaultTab":"news","newsList":[{"id":"1109161041","title":"异动解读 | 获多家机构上调评级与目标价，Dianthus Therapeutics盘中大涨5.09%","url":"https://stock-news.laohu8.com/highlight/detail?id=1109161041","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1109161041?lang=zh_cn&edition=full","pubTime":"2026-03-11 00:54","pubTimestamp":1773161689,"startTime":"0","endTime":"0","summary":"生物制药公司Dianthus Therapeutics Inc.今日盘中股价大幅上涨5.09%，引起市场关注。消息面上，投资机构Raymond James宣布将Dianthus Therapeutics的股票评级从“跑赢大盘”上调至“强力买入”，并将其目标股价从63美元大幅调高至123美元。机构分析通常基于对公司基本面、研发管线及市场潜力的评估，评级和目标价的上调往往会吸引投资者买入，从而推高股价。Dianthus Therapeutics作为一家生物制药公司，其股价对这类研究行动反应敏感。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["DNTH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1109692385","title":"Raymond James将Dianthus Therapeutics评级上调至强力买入，目标价大幅提升至123美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1109692385","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1109692385?lang=zh_cn&edition=full","pubTime":"2026-03-10 19:29","pubTimestamp":1773142181,"startTime":"0","endTime":"0","summary":"投资机构Raymond James宣布，将生物制药公司Dianthus Therapeutics Inc.（DNTH）的股票评级从“跑赢大盘”上调至“强力买入”。与此同时，该机构将其目标股价从原先的63美元显著调高至123美元，显示出对该公司未来增长前景的强烈信心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DNTH","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1161802372","title":"Dianthus Therapeutics盘后股价下挫4.1%，宣布拟进行4亿美元承销公开发行","url":"https://stock-news.laohu8.com/highlight/detail?id=1161802372","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1161802372?lang=zh_cn&edition=full","pubTime":"2026-03-10 04:37","pubTimestamp":1773088629,"startTime":"0","endTime":"0","summary":"Dianthus Therapeutics Inc. (DNTH) 在盘后交易时段股价下跌4.1%。该公司同时宣布，计划进行一笔价值4亿美元的承销公开发行。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","DNTH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1184186272","title":"Dianthus Therapeutics Inc. 计划将净收益用于临床、商业、营运资本及公司一般用途","url":"https://stock-news.laohu8.com/highlight/detail?id=1184186272","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1184186272?lang=zh_cn&edition=full","pubTime":"2026-03-10 04:02","pubTimestamp":1773086531,"startTime":"0","endTime":"0","summary":"Dianthus Therapeutics Inc. 宣布，公司拟将此次融资的净收益主要用于支持其临床项目推进、商业活动拓展、营运资本补充以及其他一般公司用途。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","DNTH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1133599026","title":"Dianthus Therapeutics公布近期业务进展，包括三期Captivate CIDP试验启动决定及2025财年第四季度和全年财务业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=1133599026","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1133599026?lang=zh_cn&edition=full","pubTime":"2026-03-09 19:11","pubTimestamp":1773054673,"startTime":"0","endTime":"0","summary":"Dianthus Therapeutics Inc. (以下简称Dianthus Therapeutics) 近日重点通报了其近期的多项业务里程碑。其中，最引人注目的是公司已正式决定推进其关键性三期临床试验——Captivate CIDP研究。此举标志着其在慢性炎症性脱髓鞘性多发性神经根神经病（CIDP）治疗领域的研发迈入决定性阶段。\n与此同时，该公司还公布了2025财年第四季度及全年的财务报告，详细披露了期间的财务状况与运营表现。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DNTH","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1124943604","title":"Dianthus Therapeutics独立数据安全监查委员会审查确认试验推进决定，未发现相关严重感染或不良事件","url":"https://stock-news.laohu8.com/highlight/detail?id=1124943604","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1124943604?lang=zh_cn&edition=full","pubTime":"2026-03-09 19:05","pubTimestamp":1773054301,"startTime":"0","endTime":"0","summary":"Dianthus Therapeutics Inc. 宣布，其独立数据安全监查委员会（DSMB）的审查结果已确认试验可继续推进。此次审查确认，试验过程中未出现任何与治疗方案相关的严重感染或不良事件。\n这一积极结果进一步支持了该临床试验的安全性评估，为后续研究阶段的顺利开展奠定了坚实基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","DNTH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1154201489","title":"Dianthus Therapeutics宣布：基于CIDP三期试验中期分析结果，决定提前推进Claseprubart研发","url":"https://stock-news.laohu8.com/highlight/detail?id=1154201489","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1154201489?lang=zh_cn&edition=full","pubTime":"2026-03-09 19:02","pubTimestamp":1773054141,"startTime":"0","endTime":"0","summary":"Dianthus Therapeutics Inc. (DNTH) 近日公布了一项重要研发进展。针对其在研药物Claseprubart用于治疗慢性炎症性脱髓鞘性多发性神经病（CIDP）的三期临床试验（CAPTIVATE研究），公司已完成一项预设的中期应答者分析。基于该分析获得的积极数据，Dianthus Therapeutics已做出“提前推进”的决策，将继续推进该临床试验的进行。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","DNTH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1108401230","title":"Dianthus Therapeutics维持300毫克/2毫升皮下注射每两周一次的剂量；计划取消600毫克/4毫升剂量组","url":"https://stock-news.laohu8.com/highlight/detail?id=1108401230","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1108401230?lang=zh_cn&edition=full","pubTime":"2026-03-09 19:02","pubTimestamp":1773054132,"startTime":"0","endTime":"0","summary":"Dianthus Therapeutics Inc. 决定继续采用其300毫克/2毫升的皮下注射方案，该方案为每两周给药一次。与此同时，公司计划停止其600毫克/4毫升的皮下注射剂量组，该组同样为每两周一次的给药频率。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DNTH","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616531388","title":"Dianthus Therapeutics, Inc.盘中异动 早盘股价大跌5.77%","url":"https://stock-news.laohu8.com/highlight/detail?id=2616531388","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616531388?lang=zh_cn&edition=full","pubTime":"2026-03-03 22:31","pubTimestamp":1772548314,"startTime":"0","endTime":"0","summary":"北京时间2026年03月03日22时31分，Dianthus Therapeutics, Inc.股票出现波动，股价急速下挫5.77%。Dianthus Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.94%。Dianthus Therapeutics, Inc.公司简介：Dianthus Therapeutics Inc 是一家临床阶段的生物技术公司，致力于设计和提供新型单克隆抗体，与现有的补体疗法相比，其选择性和效力更高。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260303223155a69dff2b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260303223155a69dff2b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4539","BK4007","LENZ","BK4139","DNTH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2607076451","title":"Dianthus Therapeutics, Inc.盘中异动 早盘股价大涨5.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2607076451","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607076451?lang=zh_cn&edition=full","pubTime":"2026-01-30 22:43","pubTimestamp":1769784220,"startTime":"0","endTime":"0","summary":"北京时间2026年01月30日22时43分，Dianthus Therapeutics, Inc.股票出现异动，股价大幅上涨5.00%。Dianthus Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.21%。Dianthus Therapeutics, Inc.公司简介：Dianthus Therapeutics Inc 是一家临床阶段的生物技术公司，致力于设计和提供新型单克隆抗体，与现有的补体疗法相比，其选择性和效力更高。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260130224340a6c0b51d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260130224340a6c0b51d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4007","BK4539","LENZ","DNTH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1141035379","title":"维立志博与Dianthus Therapeutics宣布启动LBL-047（DNTH212）在健康志愿者和系统性红斑狼疮患者中的一期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1141035379","media":"投资观察","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1141035379?lang=zh_cn&edition=full","pubTime":"2025-12-23 19:15","pubTimestamp":1766488533,"startTime":"0","endTime":"0","summary":"12月23日讯 - 南京维立志博（9887.HK）::*维立志博与Dianthus Therapeutics宣布启动LBL-047（DNTH212）在健康志愿者和系统性红斑狼疮（SLE）患者中的一期临床试验*南京维立志博有限公司：预计在2026年下半年公布健康志愿者的主要结果。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887","DNTH","BK1161","BK4139","HK0000252160.HKD","HK0000500386.USD","HK0000252152.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1161808614","title":"Leads Biolabs与Dianthus Therapeutics宣布在健康志愿者及系统性红斑狼疮患者中启动Lbl-047（Dnth212）一期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1161808614","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1161808614?lang=zh_cn&edition=full","pubTime":"2025-12-23 19:04","pubTimestamp":1766487870,"startTime":"0","endTime":"0","summary":"Leads Biolabs与Dianthus Therapeutics宣布在健康志愿者及系统性红斑狼疮患者中启动Lbl-047（Dnth212）一期临床试验。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DNTH","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517494669","title":"Dianthus Therapeutics, Inc.盘中异动 大幅拉升9.52%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517494669","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517494669?lang=zh_cn&edition=full","pubTime":"2025-03-05 22:30","pubTimestamp":1741185055,"startTime":"0","endTime":"0","summary":"北京时间2025年03月05日22时30分，Dianthus Therapeutics, Inc.股票出现异动，股价急速拉升9.52%。Dianthus Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.00%。Dianthus Therapeutics, Inc.公司简介：Dianthus Therapeutics Inc 是一家临床阶段生物技术公司，致力于设计和提供新型单克隆抗体，优化其选择性和效力并使其优于现有的补体疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305223056abe9b05d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305223056abe9b05d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","DNTH","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516308756","title":"Dianthus Therapeutics, Inc.盘中异动 早盘快速下挫5.00%报20.52美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2516308756","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516308756?lang=zh_cn&edition=full","pubTime":"2025-03-03 23:07","pubTimestamp":1741014460,"startTime":"0","endTime":"0","summary":"北京时间2025年03月03日23时07分，Dianthus Therapeutics, Inc.股票出现波动，股价大幅下跌5.00%。Dianthus Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.09%。Dianthus Therapeutics, Inc.公司简介：Dianthus Therapeutics Inc 是一家临床阶段生物技术公司，致力于设计和提供新型单克隆抗体，优化其选择性和效力并使其优于现有的补体疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303230741989a1a32&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303230741989a1a32&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","DNTH","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514387469","title":"Dianthus Therapeutics, Inc.盘中异动 临近午盘大幅拉升5.19%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514387469","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514387469?lang=zh_cn&edition=full","pubTime":"2025-02-28 00:40","pubTimestamp":1740674403,"startTime":"0","endTime":"0","summary":"北京时间2025年02月28日00时40分，Dianthus Therapeutics, Inc.股票出现异动，股价大幅拉升5.19%。Dianthus Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.61%。Dianthus Therapeutics, Inc.公司简介：Dianthus Therapeutics Inc 是一家临床阶段生物技术公司，致力于设计和提供新型单克隆抗体，优化其选择性和效力并使其优于现有的补体疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250228004003abdf8d22&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250228004003abdf8d22&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","LENZ","DNTH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514566358","title":"Dianthus Therapeutics, Inc.盘中异动 早盘急速拉升7.80%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514566358","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514566358?lang=zh_cn&edition=full","pubTime":"2025-02-26 22:31","pubTimestamp":1740580275,"startTime":"0","endTime":"0","summary":"北京时间2025年02月26日22时31分，Dianthus Therapeutics, Inc.股票出现异动，股价快速拉升7.80%。Dianthus Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.12%。Dianthus Therapeutics, Inc.公司简介：Dianthus Therapeutics Inc 是一家临床阶段生物技术公司，致力于设计和提供新型单克隆抗体，优化其选择性和效力并使其优于现有的补体疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226223115abddec78&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226223115abddec78&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BK4139","DNTH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2513778530","title":"Dianthus Therapeutics, Inc.盘中异动 早盘快速跳水5.85%报22.29美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2513778530","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2513778530?lang=zh_cn&edition=full","pubTime":"2025-02-24 23:11","pubTimestamp":1740409876,"startTime":"0","endTime":"0","summary":"北京时间2025年02月24日23时11分，Dianthus Therapeutics, Inc.股票出现波动，股价急速跳水5.85%。Dianthus Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.56%。Dianthus Therapeutics, Inc.公司简介：Dianthus Therapeutics Inc 是一家临床阶段生物技术公司，致力于设计和提供新型单克隆抗体，优化其选择性和效力并使其优于现有的补体疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224231116a2521e62&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224231116a2521e62&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","DNTH","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2512481862","title":"Dianthus Therapeutics, Inc.盘中异动 早盘股价大跌5.82%","url":"https://stock-news.laohu8.com/highlight/detail?id=2512481862","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2512481862?lang=zh_cn&edition=full","pubTime":"2025-02-19 23:51","pubTimestamp":1739980266,"startTime":"0","endTime":"0","summary":"北京时间2025年02月19日23时51分，Dianthus Therapeutics, Inc.股票出现波动，股价快速跳水5.82%。Dianthus Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.51%。Dianthus Therapeutics, Inc.公司简介：Dianthus Therapeutics Inc 是一家临床阶段生物技术公司，致力于设计和提供新型单克隆抗体，优化其选择性和效力并使其优于现有的补体疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250219235106abd50f87&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250219235106abd50f87&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","LENZ","DNTH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2511815577","title":"Dianthus Therapeutics, Inc.盘中异动 临近收盘大幅拉升5.00%报24.16美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2511815577","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2511815577?lang=zh_cn&edition=full","pubTime":"2025-02-14 05:00","pubTimestamp":1739480416,"startTime":"0","endTime":"0","summary":"北京时间2025年02月14日05时00分，Dianthus Therapeutics, Inc.股票出现波动，股价急速拉升5.00%。Dianthus Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为1.20%。Dianthus Therapeutics, Inc.公司简介：Dianthus Therapeutics Inc 是一家临床阶段生物技术公司，致力于设计和提供新型单克隆抗体，优化其选择性和效力并使其优于现有的补体疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502140500179884777e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502140500179884777e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["DNTH","BK4139","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2509786830","title":"Dianthus Therapeutics, Inc.盘中异动 下午盘股价大跌5.74%","url":"https://stock-news.laohu8.com/highlight/detail?id=2509786830","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2509786830?lang=zh_cn&edition=full","pubTime":"2025-02-07 04:11","pubTimestamp":1738872676,"startTime":"0","endTime":"0","summary":"北京时间2025年02月07日04时11分，Dianthus Therapeutics, Inc.股票出现波动，股价快速下跌5.74%。Dianthus Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.59%。Dianthus Therapeutics, Inc.公司简介：Dianthus Therapeutics Inc 是一家临床阶段生物技术公司，致力于设计和提供新型单克隆抗体，优化其选择性和效力并使其优于现有的补体疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250207041116a23c1271&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250207041116a23c1271&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","DNTH","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.magentatx.com","stockEarnings":[{"period":"1week","weight":-0.0719},{"period":"1month","weight":0.0313},{"period":"3month","weight":0.6568},{"period":"6month","weight":1.4798},{"period":"1year","weight":2.9007},{"period":"ytd","weight":1.0303}],"compareEarnings":[{"period":"1week","weight":0.0108},{"period":"1month","weight":0.1224},{"period":"3month","weight":0.0234},{"period":"6month","weight":0.0469},{"period":"1year","weight":0.292},{"period":"ytd","weight":0.0437}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Dianthus Therapeutics, Inc.于2015年6月17日根据特拉华州法律注册成立。该公司是一家临床阶段的生物技术公司，开发新药，为更多的患者带来骨髓移植的治疗能力。该公司打算成为移植医学领域的完全整合的发现，开发和商业公司。该公司相信产品组合将提供显著的商业协同效应。 该公司正在开发产品，以便可以单独使用或相互结合使用。因此，该公司的投资组合可以以适合患者疾病的方式使用，以便患者可以接受多于一种洋红疗法作为其个人移植旅程的一部分。","yearOnYearQuotes":[{"month":1,"riseRate":0.75,"avgChangeRate":0.175283},{"month":2,"riseRate":0.625,"avgChangeRate":0.224994},{"month":3,"riseRate":0.5,"avgChangeRate":0.049298},{"month":4,"riseRate":0.25,"avgChangeRate":-0.056392},{"month":5,"riseRate":0.571429,"avgChangeRate":-0.056052},{"month":6,"riseRate":0.714286,"avgChangeRate":0.017401},{"month":7,"riseRate":0.625,"avgChangeRate":0.0311},{"month":8,"riseRate":0.5,"avgChangeRate":-0.011939},{"month":9,"riseRate":0.375,"avgChangeRate":0.056023},{"month":10,"riseRate":0.25,"avgChangeRate":-0.093611},{"month":11,"riseRate":0.5,"avgChangeRate":0.042669},{"month":12,"riseRate":0.25,"avgChangeRate":-0.158671}],"exchange":"NASDAQ","name":"Dianthus Therapeutics Inc.","nameEN":"Dianthus Therapeutics Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Dianthus Therapeutics Inc.(DNTH)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Dianthus Therapeutics Inc.(DNTH)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Dianthus Therapeutics Inc.,DNTH,Dianthus Therapeutics Inc.股票,Dianthus Therapeutics Inc.股票老虎,Dianthus Therapeutics Inc.股票老虎国际,Dianthus Therapeutics Inc.行情,Dianthus Therapeutics Inc.股票行情,Dianthus Therapeutics Inc.股价,Dianthus Therapeutics Inc.股市,Dianthus Therapeutics Inc.股票价格,Dianthus Therapeutics Inc.股票交易,Dianthus Therapeutics Inc.股票购买,Dianthus Therapeutics Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Dianthus Therapeutics Inc.(DNTH)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Dianthus Therapeutics Inc.(DNTH)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}